Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

Human parainfluenza virus type 1 (hPIV-1) is the most common cause of laryngotracheobronchitis (croup), resulting in tens of thousands of hospitalizations each year in the United States alone. No licensed vaccine is yet available. We have developed murine PIV-1 (Sendai virus [SeV]) as a live Jenneri...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Vaccine Immunol
Päätekijät: Adderson, Elisabeth, Branum, Kristen, Sealy, Robert E., Jones, Bart G., Surman, Sherri L., Penkert, Rhiannon, Freiden, Pamela, Slobod, Karen S., Gaur, Aditya H., Hayden, Randall T., Allison, Kim, Howlett, Nanna, Utech, Jill, Allay, Jim, Knight, James, Sleep, Susan, Meagher, Michael M., Russell, Charles J., Portner, Allen, Hurwitz, Julia L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2015
Aiheet:
Vaccines
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4340902/
https://ncbi.nlm.nih.gov/pubmed/25552633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00618-14
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
Lataa...

Samankaltaisia teoksia